World Cervical Cancer Day, 2026

World Cervical Cancer Day, 2026

Cervical cancer is a malignant disease arising from cells of the uterine cervix, the lower part of the uterus that connects with the vagina. It usually develops gradually through precancerous cellular changes, many of which can be detected and treated before invasive cancer occurs. This long pre-invasive phase creates an important opportunity for prevention through HPV vaccination and organised screening. Cervical cancer is therefore distinctive among major cancers because effective primary and secondary prevention interventions are available and can substantially reduce incidence and mortality when implemented equitably (World Health Organization [WHO], 2026).

Despite its preventability, cervical cancer continues to cause substantial illness, premature death, financial hardship and social disruption. The disease disproportionately affects populations with limited access to vaccination, screening, diagnostic services and timely treatment. These inequities are associated with poverty, gender inequality, weak health systems and differences in health literacy. In Nigeria, cervical cancer remains an important cause of cancer morbidity and mortality among women, making prevention and early detection critical public health priorities (Federal Ministry of Health, 2025; WHO, 2021a).

This review synthesises available literature on cervical cancer, moving from its biological basis to prevention and control. Particular attention is given to Nigerian evidence because national context influences the feasibility, acceptability and effectiveness of interventions.

The cervix contains different epithelial cell types, and most cervical cancers develop in the transformation zone, where glandular and squamous epithelial cells meet. Persistent infection with high-risk HPV can disrupt normal cellular regulation and produce precancerous lesions. If these lesions are not detected and managed, some may progress over several years to invasive cancer. The most common histological types are squamous cell carcinoma and adenocarcinoma, although other less common forms occur.

HPV is a group of viruses transmitted mainly through intimate skin-to-skin or sexual contact. Infection is common, and most infections are transient because the immune system clears them. The major concern is persistent infection with oncogenic HPV types. HPV 16 and 18 account for a large proportion of cervical cancers, while other high-risk types also contribute to disease burden (WHO, 2026; IARC, 2026). Infection alone does not mean that a person will develop cancer; persistence, host factors and other cofactors influence progression.

Recent WHO estimates indicate approximately 604,000 new cervical cancer cases and about 280,000 deaths worldwide in 2024. The burden is not evenly distributed: incidence and mortality are highest in low- and middle-income settings, where access to vaccination, screening, pathology, surgery, radiotherapy and systemic treatment is often limited (WHO, 2026). IARC similarly emphasises that the overwhelming majority of cervical cancer cases and deaths occur in low- and middle-income countries (IARC, 2026).

These patterns demonstrate that cervical cancer is not simply a biological problem. They reflect unequal access to preventive and curative services and the influence of social determinants of health. Countries with organised screening, high vaccination coverage and effective treatment pathways have achieved substantial reductions in disease burden. Conversely, health systems that depend largely on opportunistic screening may fail to reach women who are most vulnerable.

Nigeria faces a considerable cervical cancer burden. WHO country-profile estimates reported approximately 10,600 cervical cancer deaths in 2019 and an age-standardised incidence rate of 18.4 per 100,000 women in 2020; the profile also documented low screening coverage, with 11% of women aged 30–49 screened in the preceding five years (WHO, 2021b). These figures are historical country-profile estimates and should not be interpreted as current annual counts.

At the 2025 World Health Assembly, Nigeria reported an estimated 12,000 new cases and more than 8,000 deaths annually, while reaffirming alignment with the WHO 90–70–90 elimination targets. The Federal Ministry of Health also reported that the national HPV vaccination rollout had reached approximately 12 million girls by the time of the statement (Federal Ministry of Health, 2025). Differences between estimates across years and sources may arise from modelling methods, reporting periods and improved data. They underline the importance of strengthening cancer registration and surveillance.

HPV vaccination was introduced into Nigeria's routine immunisation system in 2023, initially through a phased campaign targeting girls aged 9–14 years. WHO reported that the first phase reached 4.7 million girls across 16 states between October 2023 and January 2024 (WHO Regional Office for Africa, 2024). Sustaining coverage, reaching out-of-school girls and integrating vaccination into routine services remain important implementation priorities.

Persistent infection with high-risk HPV is the necessary causal factor in almost all cases of cervical cancer. However, progression from infection to precancer and invasive disease is influenced by several cofactors. These include HIV-related immunosuppression, other causes of reduced immune function, tobacco smoking, and reproductive and sexual health factors that may increase the probability of HPV exposure or persistence. Women living with HIV have a substantially increased risk of cervical cancer compared with women without HIV (WHO, 2026).

Other factors commonly discussed in the literature include early sexual debut, multiple sexual partners, high parity and prolonged use of some hormonal contraceptives. These factors should be interpreted carefully: they do not independently cause cervical cancer in the absence of oncogenic HPV, and associations may be influenced by confounding. Social determinants such as poverty, limited education, stigma and poor access to preventive services increase vulnerability by reducing opportunities for vaccination, screening and early treatment.

Early cervical precancer and early invasive disease may produce no noticeable symptoms. This absence of symptoms is a major reason screening is necessary even when a woman feels healthy. When symptoms occur, they may include bleeding after sexual intercourse, bleeding between menstrual periods or after menopause, persistent or unusual vaginal discharge, pelvic pain and pain during intercourse. Advanced disease may cause persistent back or leg pain, swelling of the legs, weight loss, fatigue, loss of appetite or urinary and bowel symptoms (WHO, 2026).

These symptoms are not specific to cervical cancer and may occur in other conditions. They require prompt clinical assessment rather than self-diagnosis. Public education should therefore encourage timely consultation while avoiding messages that create unnecessary fear or stigma.

Cervical screening aims to identify high-risk HPV infection or precancerous changes before invasive disease develops. Available approaches include HPV DNA testing, cytology (Pap testing) and visual inspection with acetic acid (VIA). WHO recommends HPV DNA testing as the preferred primary screening method where feasible because it is more sensitive than visual inspection or cytology and can support longer screening intervals. Screening strategies should be adapted to national resources and the needs of the population (WHO, 2021a).

WHO guidance recommends starting regular screening at age 30 in the general population and at age 25 for women living with HIV, with intervals depending on the test and national protocol. The global elimination strategy calls for women to be screened with a high-performance test by age 35 and again by age 45. A positive screening result is not itself a diagnosis of cancer; it requires appropriate triage, diagnostic assessment and, where indicated, treatment of precancerous lesions.

Self-collection for HPV testing may improve participation by reducing discomfort, embarrassment and practical barriers. Screen-and-treat approaches can also reduce loss to follow-up in settings where women face transport costs or repeated clinic visits. However, programmes must ensure quality assurance, informed consent, privacy, clear communication of results and access to treatment after a positive screen.

Primary prevention is centred on HPV vaccination before exposure to the virus. WHO recommends vaccination for girls aged 9–14 years, with schedules determined by national guidance and individual clinical circumstances. Vaccination does not remove the need for future screening because vaccines do not protect against every oncogenic HPV type and do not treat an infection already present (WHO, 2026).

Secondary prevention involves screening and treatment of precancerous lesions. Thermal ablation, cryotherapy, loop electrosurgical excision and cone biopsy are among the methods used, depending on lesion characteristics, clinical guidance and available expertise. Tertiary prevention requires timely diagnosis, staging, treatment and supportive or palliative care for women with invasive disease. Treatment may involve surgery, radiotherapy, chemotherapy or combinations of these modalities.

At population level, effective control requires an integrated programme rather than isolated campaigns. Essential components include reliable vaccine procurement, school- and community-based delivery, public education, affordable screening, trained providers, pathology services, referral systems, cancer treatment capacity and monitoring of coverage and outcomes.

Treatment depends on stage, tumour characteristics, the patient's overall health and reproductive preferences. Early-stage disease may be managed with surgery or radiotherapy, while locally advanced disease commonly requires concurrent chemoradiotherapy. Systemic therapy and palliative interventions may be required for recurrent or metastatic disease. Clinical decisions should be made by appropriately trained multidisciplinary teams and follow evidence-based national or international guidelines.

Supportive care is important throughout the disease pathway. It includes management of pain and other symptoms, psychological support, counselling, sexual and reproductive health care, social support and palliative care when needed. Delays between diagnosis and treatment can reduce the likelihood of favourable outcomes, making referral coordination and treatment affordability central elements of cancer control

Evidence from Nigerian systematic reviews identifies multiple, overlapping barriers to cervical screening. Mafiana et al. (2022), reviewing 15 studies involving 9,995 women, reported lack of knowledge, misconceptions, fear of the procedure or result, perceptions that screening was unnecessary, financial constraints and health-service factors. A separate systematic review among female health workers found that even relatively knowledgeable participants had low screening uptake; reported barriers included cost, fear of a positive result, lack of awareness of screening options, low perceived risk and lack of time (Adewumi et al., 2021).

These findings suggest that information campaigns alone are insufficient. Women may understand that screening exists but still be unable to afford it, reach a facility, obtain an appointment or complete follow-up. Provider attitudes, privacy, availability of female providers, waiting times, equipment, laboratory capacity and continuity of care may influence service use. Cultural and religious beliefs and concerns about stigma can also shape decisions, and should be addressed through respectful community engagement rather than blame.

Policy and programme responses should therefore combine demand-side strategies with health-system strengthening. These include integrating screening into primary health care and HIV services, reducing out-of-pocket costs, training providers, expanding HPV testing, improving referral and tracking systems, and engaging community, religious and women's organisations.

References

Adewumi, K., Oketch, S. Y., & colleagues. (2021). Factors influencing cervical cancer screening practice among female health workers in Nigeria: A systematic review. *Cancer Reports*. https://pmc.ncbi.nlm.nih.gov/articles/PMC9124499/

Federal Ministry of Health. (2025). *Statement by Nigeria: Agenda item 13.1—Global strategy on cervical cancer elimination*. World Health Assembly. https://apps.who.int/gb/statements/WHA78/PDF/Nigeria-13.1b.pdf

International Agency for Research on Cancer. (2026). *Cervical cancer*. https://www.iarc.who.int/cancer-type/cervical-cancer/

Mafiana, J. J., Dhital, S., Halabia, M., & Wang, X. (2022). Barriers to uptake of cervical cancer screening among women in Nigeria: A systematic review. *African Health Sciences, 22*(2), 295–309. https://doi.org/10.4314/ahs.v22i2.33

World Health Organization. (2021a). *WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention* (2nd ed.). https://www.who.int/publications/i/item/9789240030824

World Health Organization. (2021b). *Nigeria: Cervical cancer country profile*. https://cdn.who.int/media/docs/default-source/country-profiles/cervical-cancer/cervical-cancer-nga-2021-country-profile-en.pdf

World Health Organization. (2026, November 10). *Cervical cancer*. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

World Health Organization, Regional Office for Africa. (2024). *Nigeria: Safeguarding the future of women and girls against cervical cancer*. https://www.afro.who.int/sites/default/files/2024-03/WHO%20AFRO%20Investment%20Case%20Series_Cervical%20Cancer%20and%20HPV%20Vaccination.pdf